thiophene-3-carboximidothioic acid benzyl ester hydrobromide | 915037-96-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: thiophene-3-carboximidothioic acid benzyl ester hydrobromide
• 英文别名: benzyl thiophene-3-carboximidothioate;hydrobromide
• CAS: 915037-96-6
• 化学式: BrH*C₁₂H₁₁NS₂
• 分子量: 314.27
• InChiKey: QAUXHSTYLGTOIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.58
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  77.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  thiophene-3-carboximidothioic acid benzyl ester hydrobromide 、 1-[2-(diethylamino)ethyl]-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-amine 在 sodium hydroxide 作用下， 以 乙醇 、 水 、 乙酸乙酯 为溶剂， 反应 108.0h， 以30.8%的产率得到N-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)thiophen-3-carboximidamide
  参考文献：
  名称：

  Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity

  摘要：

  本发明涉及具有双重一氧化氮合酶（NOS）抑制活性和μ-阿片受体激动活性的苯并咪唑化合物，以及包含它们的药物和诊断组合物，以及它们的医学用途，特别是作为治疗或预防慢性疼痛、急性疼痛、偏头痛和神经病性疼痛的化合物。

  公开号：

  US20080214613A1

文献信息

• Substituted indole compounds having NOS inhibitory activity
  申请人：Maddaford Shawn

  公开号：US20060258721A1

  公开（公告）日：2006-11-16

  The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

  本发明涉及一种一氧化氮合酶（NOS）的抑制剂，特别是那些选择性地抑制神经型一氧化氮合酶（nNOS）而不是其他NOS同工酶的抑制剂。本发明的NOS抑制剂，单独或与其他药用活性剂结合使用，可用于治疗或预防诸如中风、再灌注损伤、神经退行性疾病、头部创伤、冠状动脉搭桥术（CABG）、伴或不伴有先兆的偏头痛、伴有疼痛性过敏的偏头痛、中枢性中风后疼痛（CPSP）、神经痛、吗啡/阿片类药物引起的耐受性和过度疼痛等疾病。
• SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY
  申请人：Maddaford Shawn

  公开号：US20080249302A1

  公开（公告）日：2008-10-09

  The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

  本发明涉及一种一氧化氮合酶（NOS）抑制剂，特别是那些选择性地抑制神经元一氧化氮合酶（nNOS）而不是其他NOS亚型。本发明的NOS抑制剂，单独或与其他药理活性剂联合使用，可用于治疗或预防诸如中风、再灌注损伤、神经退行性疾病、头部创伤、CABG、偏头痛（有和无先兆）、伴有痛觉过敏的偏头痛、中枢后中风疼痛（CPSP）、神经病性疼痛、吗啡/阿片类药物引起的耐受和高敏感性等疾病。
• 1,6-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase inhibitors
  作者：Shawn Maddaford、Paul Renton、Joanne Speed、Subhash C. Annedi、Jailall Ramnauth、Suman Rakhit、John Andrews、Gabriela Mladenova、Lisa Majuta、Frank Porreca

  DOI：10.1016/j.bmcl.2011.07.042

  日期：2011.9

  A series of 1,6-disubstituted indole derivatives was designed, synthesized and evaluated as inhibitors of human nitric oxide synthase (NOS). By varying the basic amine side chain at the 1-position of the indole ring, several potent and selective inhibitors of human neuronal NOS were identified. In general compounds with bulkier side chains displayed increased selectivity for nNOS over eNOS and iNOS isoforms. One of the compounds, (R)-8 was shown to reduce tactile hyperesthesia (allodynia) after oral administration (30 mg/kg) in an in vivo rat model of dural inflammation relevant to migraine pain. (C) 2011 Elsevier Ltd. All rights reserved.
• US7375219B2
  申请人：——

  公开号：US7375219B2

  公开（公告）日：2008-05-20
• US7951940B2
  申请人：——

  公开号：US7951940B2

  公开（公告）日：2011-05-31